Developer docs
API playgroundTry for free, no card

Search company profiles

Earendil Labs

Full company profile

uuid006dxwn

Namestring
Earendil Labs
Legal namestring
Earendil Labs
Websiteurl
earendil.bio
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Earendil Labs is a private, AI-driven biotechnology company founded in 2021 that designs and develops antibody and protein therapeutics for autoimmune, inflammatory, and oncology indications. Its core offering is an integrated biologics discovery platform that combines deep learning, generative protein engineering, structural biology, and high-throughput experimental validation in a closed design-build-test loop. The company positions itself as an AI-native biotech, not a tooling vendor: the same platform that produces candidates also generates the wet-lab data that retrain it.

The pipeline comprises 40+ disclosed biologics programs spanning multiple modalities — half-life-extended monoclonal antibodies (HXN-1001 anti-TL1A; HXN-1021 anti-OX40L), biparatopic antibodies (HXN-1011 anti-TSLP), bispecific antibodies (HX-16108 IL-13/IL-31), and T-cell engagers (HXN-1031 CD19/BCMA). Two programs are in the clinic as of mid-2026: HXN-1001 in Phase IIa for ulcerative colitis and HXN-1011 in Phase I for immunological disorders, with multiple IND submissions planned for 2026–2027. Manufacturing and ADC payloads are accessed via exclusive partnerships with WuXi Biologics (end-to-end bispecific/multispecific and ADC manufacturing) and WuXi XDC (exclusive global license to WuXiTecan-2 payload-linker technology).

Earendil is a B2B licensing biotech that monetizes its pipeline almost exclusively through strategic collaborations with large pharmaceutical companies, generating revenue through upfront payments, development and commercial milestones, and tiered royalties on net sales. Its flagship deal with Sanofi, signed in January 2026, is worth up to $2.56 billion for bispecific antibodies in autoimmune/inflammatory disease, supplementing an earlier ~$1.7 billion Sanofi autoimmune/inflammatory agreement. The company operates a multipolar footprint — Delaware incorporation, Beijing operational base affiliated with Helixon Therapeutics (华深智药), and Australian clinical sites — and raised $787 million in March 2026 to scale platform, pipeline, and headcount. It is reportedly considering a Hong Kong IPO.

Short descriptiontext

Earendil Labs is a private AI-driven biotechnology company that designs antibody and protein therapeutics for autoimmune, inflammatory, and oncology indications, licensing discovered candidates to large pharmaceutical partners (notably Sanofi) via upfront, milestone, and royalty agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMiddletown, United States
HQ citystring
Middletown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, biologics discovery, antibody engineering, protein therapeutics, antibody-drug conjugates
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biologics Drug Discovery
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Strategic Partnerships and Licensing
TypeLicensing Royalties
Description

Earendil generates revenue through strategic collaborations with pharmaceutical companies including upfront payments, development and commercial milestone payments, and tiered royalties on net product sales. Notable deals include Sanofi's up to $2.56 billion collaboration.

prnewswire.com
2Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary AI platforms and discovered molecules to pharmaceutical partners for development and commercialization

vcnewsdaily.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Earendil Labs develops an AI-driven biologics discovery platform that combines deep learning, generative protein engineering, structural biology, and high-throughput experimental validation to discover and optimize novel antibody therapeutics. The company applies this platform to build a pipeline of more than 40 biologics programs across autoimmune, inflammatory, and oncology indications, which it out-licenses to large pharmaceutical partners for development and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 40+ biologics programs in pipeline
+2 more records
Product overview1 text field

Earendil Labs is an AI-driven biotechnology company developing a portfolio of antibody and biologics programs. The company's pipeline includes over 40 programs spanning multiple modalities: HXN-1001 (anti-TL1A antibody for IBD in Phase II), HXN-1011 (anti-TSLP biparatopic antibody in Phase I), HXN-1021 (anti-OX40L antibody), HX-16108 (bispecific IL-13/IL-31 antibody), and HXN-1031 (CD19/BCMA bispecific T-cell engager for B-cell malignancies). The AI platform integrates deep learning, generative protein engineering, structural biology, and high-throughput experimental validation for antibody discovery and optimization, with strategic manufacturing partnerships with WuXi Biologics and WuXi XDC leveraging WuXiTecan-2 ADC technology.

Product and service5 records
1HXN-1001
CategoryCore biologic candidate
Description

Half-life extended anti-TL1A antibody being developed for ulcerative colitis and inflammatory bowel disease, with Phase I data showing approximately 8-week half-life and a well-tolerated safety profile.

2HXN-1011
CategoryCore biologic candidate
Description

Biparatopic antibody targeting TSLP for immunological disorders including asthma, atopic dermatitis, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and COPD.

3HXN-1021
CategoryCore biologic candidate
Description

Anti-OX40L antibody with potent activity and extended half-life targeting the OX40L-OX40 T-cell costimulatory pathway implicated in multiple autoimmune diseases including atopic dermatitis.

4HX-16108
CategoryCore biologic candidate
Description

Bispecific antibody targeting both IL-13 and IL-31 cytokines for atopic dermatitis and inflammatory skin diseases with pruritus.

5HXN-1031
CategoryCore biologic candidate
Description

Bispecific T-cell engager targeting both CD19 and B-cell maturation protein (BCMA) for B-cell malignancies.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

Strategic collaboration for development and manufacturing of bispecific/multispecific antibodies and ADCs targeting autoimmune disease, cancer, and other diseases. WuXi Biologics provides end-to-end biologics development and manufacturing services including cell line development, process development, and GMP manufacturing.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-02-27
Description

Exclusive global license to WuXiTecan-2 payload-linker technology platform for developing next-generation ADCs. Total potential deal value up to $885 million including upfront, milestone payments, and tiered royalties. WuXi XDC supports CMC development and manufacturing while Earendil leads product development and commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-05
Description

Strategic collaboration to discover bispecific antibodies for autoimmune and inflammatory diseases. Sanofi leads development and worldwide commercialization. Deal includes up to $160 million upfront with total potential value reaching $2.56 billion plus tiered royalties on net product sales.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Prior licensing agreements for autoimmune and inflammatory disease programs including a $1.7 billion licensing deal, establishing ongoing strategic relationship with Sanofi.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

AI-driven antibody engineering platform combining ML-guided design with high-throughput wet-lab validation. Smaller and earlier-stage than Earendil but highly comparable in core technology approach — generative protein engineering with tight computational-experimental iteration loops for antibody optimization.

TypeDirect peer
Description

AI-driven drug discovery company combining machine learning with high-throughput biology to discover and develop therapeutics. Comparable as a direct AI-biologics platform peer with pharma partnerships and venture-scale funding, though Insitro's pipeline is weighted toward small-molecule and metabolic disease rather than antibody discovery.

3Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed AI drug discovery company applying DeepMind's protein-structure prediction to therapeutic discovery with pharma partnerships including Novartis and Eli Lilly. Comparable as a generative biology platform peer, though with substantially greater capital backing and broader partnership scope.

TypeDirect peer
Description

Generative AI platform for protein therapeutics design with pharma partnerships including Amgen and Eli Lilly. Highly comparable — both companies use generative protein engineering to design novel antibodies and biologics for licensing to large pharma, and both emphasize platform productivity as a core metric.

5Antiverse
TypeEmerging player
Description

AI-based antibody discovery platform using generative models to design antibody candidates. Comparable as an emerging AI-antibody-design peer, though substantially smaller and earlier-stage than Earendil with no disclosed late-stage clinical assets.

TypeDirect peer
Description

Industry-leading antibody discovery and engineering platform that licenses antibody candidates to pharma partners. Comparable as a discovery-platform business model peer (licensing/royalty revenue, no direct commercialization), though Adimab emphasizes wet-lab technology and yeast-display rather than AI-driven design.

TypeDirect peer
Description

Pure-play antibody discovery platform using high-throughput single-cell screening, AI, and engineering to discover therapeutic antibodies for pharma partners. Most directly comparable peer — both monetize via licensing to large pharma and operate technology platforms producing antibody candidates across multiple indications.

TypeEmerging player
Description

AI protein language model company developing foundation models for protein design, with applications in therapeutic discovery. Comparable as a frontier-AI-protein-design peer intersecting with Earendil's generative engineering focus, though primarily infrastructure-oriented rather than a pipeline developer.

TypeDirect peer
Description

AI-first drug discovery company launched in 2024 with $1B Series A, applying generative AI to protein design and small-molecule discovery. Comparable as a recently-funded generative-AI-biologics peer with similar platform ambitions and pharma partnership strategy, though earlier in commercial validation.

TypeDirect peer
Description

AI-enabled drug discovery company combining high-dimensional biology, chemistry, and ML to discover therapeutics across multiple modalities. Comparable as a publicly-traded AI-drug-discovery peer with a similar platform-licensing and pipeline-development business model, though Recursion's pipeline is more small-molecule weighted.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Earendil Labs

Biologics Drug Discoveryearendil.bio

Earendil Labs is a private AI-driven biotechnology company that designs antibody and protein therapeutics for autoimmune, inflammatory, and oncology indications, licensing discovered candidates to large pharmaceutical partners (notably Sanofi) via upfront, milestone, and royalty agreements.

What Earendil Labs does

Earendil Labs is a private, AI-driven biotechnology company founded in 2021 that designs and develops antibody and protein therapeutics for autoimmune, inflammatory, and oncology indications. Its core offering is an integrated biologics discovery platform that combines deep learning, generative protein engineering, structural biology, and high-throughput experimental validation in a closed design-build-test loop. The company positions itself as an AI-native biotech, not a tooling vendor: the same platform that produces candidates also generates the wet-lab data that retrain it.

The pipeline comprises 40+ disclosed biologics programs spanning multiple modalities — half-life-extended monoclonal antibodies (HXN-1001 anti-TL1A; HXN-1021 anti-OX40L), biparatopic antibodies (HXN-1011 anti-TSLP), bispecific antibodies (HX-16108 IL-13/IL-31), and T-cell engagers (HXN-1031 CD19/BCMA). Two programs are in the clinic as of mid-2026: HXN-1001 in Phase IIa for ulcerative colitis and HXN-1011 in Phase I for immunological disorders, with multiple IND submissions planned for 2026–2027. Manufacturing and ADC payloads are accessed via exclusive partnerships with WuXi Biologics (end-to-end bispecific/multispecific and ADC manufacturing) and WuXi XDC (exclusive global license to WuXiTecan-2 payload-linker technology).

Earendil is a B2B licensing biotech that monetizes its pipeline almost exclusively through strategic collaborations with large pharmaceutical companies, generating revenue through upfront payments, development and commercial milestones, and tiered royalties on net sales. Its flagship deal with Sanofi, signed in January 2026, is worth up to $2.56 billion for bispecific antibodies in autoimmune/inflammatory disease, supplementing an earlier ~$1.7 billion Sanofi autoimmune/inflammatory agreement. The company operates a multipolar footprint — Delaware incorporation, Beijing operational base affiliated with Helixon Therapeutics (华深智药), and Australian clinical sites — and raised $787 million in March 2026 to scale platform, pipeline, and headcount. It is reportedly considering a Hong Kong IPO.

Earendil Labs firmographics

Firmographics
Name
Earendil Labs
Legal name
Earendil Labs
Website
https://earendil.bio
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Earendil Labs is a private AI-driven biotechnology company that designs antibody and protein therapeutics for autoimmune, inflammatory, and oncology indications, licensing discovered candidates to large pharmaceutical partners (notably Sanofi) via upfront, milestone, and royalty agreements.
Ownership category
akta.pro rank

Earendil Labs industry classification

Industry
Product category
Biologics Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Biologics discovery
  • Antibody engineering
  • Protein therapeutics
  • Antibody-drug conjugates

Where Earendil Labs is headquartered

Location

Headquarters

HQ city
Middletown
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Earendil Labs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Strategic Partnerships and Licensing: Earendil generates revenue through strategic collaborations with pharmaceutical companies including upfront payments, development and commercial milestone payments, and tiered royalties on net product sales. Notable deals include Sanofi's up to $2.56 billion collaboration.
  2. Technology Licensing: Licensing of proprietary AI platforms and discovered molecules to pharmaceutical partners for development and commercialization

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Earendil Labs product offering

Product offering

Core offering

Earendil Labs develops an AI-driven biologics discovery platform that combines deep learning, generative protein engineering, structural biology, and high-throughput experimental validation to discover and optimize novel antibody therapeutics. The company applies this platform to build a pipeline of more than 40 biologics programs across autoimmune, inflammatory, and oncology indications, which it out-licenses to large pharmaceutical partners for development and commercialization.

Product overview

Earendil Labs is an AI-driven biotechnology company developing a portfolio of antibody and biologics programs. The company's pipeline includes over 40 programs spanning multiple modalities: HXN-1001 (anti-TL1A antibody for IBD in Phase II), HXN-1011 (anti-TSLP biparatopic antibody in Phase I), HXN-1021 (anti-OX40L antibody), HX-16108 (bispecific IL-13/IL-31 antibody), and HXN-1031 (CD19/BCMA bispecific T-cell engager for B-cell malignancies). The AI platform integrates deep learning, generative protein engineering, structural biology, and high-throughput experimental validation for antibody discovery and optimization, with strategic manufacturing partnerships with WuXi Biologics and WuXi XDC leveraging WuXiTecan-2 ADC technology.

Differentiator

Problem solved

Functional benefit

Products and services

  • HXN-1001 Half-life extended anti-TL1A antibody being developed for ulcerative colitis and inflammatory bowel disease, with Phase I data showing approximately 8-week half-life and a well-tolerated safety profile.
  • HXN-1011 Biparatopic antibody targeting TSLP for immunological disorders including asthma, atopic dermatitis, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and COPD.
  • HXN-1021 Anti-OX40L antibody with potent activity and extended half-life targeting the OX40L-OX40 T-cell costimulatory pathway implicated in multiple autoimmune diseases including atopic dermatitis.
  • HX-16108 Bispecific antibody targeting both IL-13 and IL-31 cytokines for atopic dermatitis and inflammatory skin diseases with pruritus.
  • HXN-1031 Bispecific T-cell engager targeting both CD19 and B-cell maturation protein (BCMA) for B-cell malignancies.

Quantifiable outcome

  • 40+ biologics programs in pipeline
  • +2 more outcomes

Companies that use Earendil Labs

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Earendil Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Earendil Labs partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • WuXi BiologicscoreStrategic or Co-development Partner · 12 March 2026Strategic collaboration for development and manufacturing of bispecific/multispecific antibodies and ADCs targeting autoimmune disease, cancer, and other diseases. WuXi Biologics provides end-to-end biologics development and manufacturing services including cell line development, process development, and GMP manufacturing.
  • WuXi XDCcoreOEM/ Whitelabel/ Licensing Partner · 27 February 2026Exclusive global license to WuXiTecan-2 payload-linker technology platform for developing next-generation ADCs. Total potential deal value up to $885 million including upfront, milestone payments, and tiered royalties. WuXi XDC supports CMC development and manufacturing while Earendil leads product development and commercialization.
  • SanoficoreStrategic or Co-development Partner · 5 January 2026Strategic collaboration to discover bispecific antibodies for autoimmune and inflammatory diseases. Sanofi leads development and worldwide commercialization. Deal includes up to $160 million upfront with total potential value reaching $2.56 billion plus tiered royalties on net product sales.
  • SanoficoreStrategic or Co-development Partner · 1 January 2025Prior licensing agreements for autoimmune and inflammatory disease programs including a $1.7 billion licensing deal, establishing ongoing strategic relationship with Sanofi.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Earendil Labs competitors and assessment

Company assessment

Emerging players

  • BigHat Biosciences: AI-driven antibody engineering platform combining ML-guided design with high-throughput wet-lab validation. Smaller and earlier-stage than Earendil but highly comparable in core technology approach — generative protein engineering with tight computational-experimental iteration loops for antibody optimization.
  • Antiverse: AI-based antibody discovery platform using generative models to design antibody candidates. Comparable as an emerging AI-antibody-design peer, though substantially smaller and earlier-stage than Earendil with no disclosed late-stage clinical assets.
  • EvolutionaryScale (ESM): AI protein language model company developing foundation models for protein design, with applications in therapeutic discovery. Comparable as a frontier-AI-protein-design peer intersecting with Earendil's generative engineering focus, though primarily infrastructure-oriented rather than a pipeline developer.

Direct peers

  • Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to discover and develop therapeutics. Comparable as a direct AI-biologics platform peer with pharma partnerships and venture-scale funding, though Insitro's pipeline is weighted toward small-molecule and metabolic disease rather than antibody discovery.
  • Isomorphic Labs: Alphabet-backed AI drug discovery company applying DeepMind's protein-structure prediction to therapeutic discovery with pharma partnerships including Novartis and Eli Lilly. Comparable as a generative biology platform peer, though with substantially greater capital backing and broader partnership scope.
  • Generate Biomedicines: Generative AI platform for protein therapeutics design with pharma partnerships including Amgen and Eli Lilly. Highly comparable — both companies use generative protein engineering to design novel antibodies and biologics for licensing to large pharma, and both emphasize platform productivity as a core metric.
  • Adimab: Industry-leading antibody discovery and engineering platform that licenses antibody candidates to pharma partners. Comparable as a discovery-platform business model peer (licensing/royalty revenue, no direct commercialization), though Adimab emphasizes wet-lab technology and yeast-display rather than AI-driven design.
  • AbCellera Biologics: Pure-play antibody discovery platform using high-throughput single-cell screening, AI, and engineering to discover therapeutic antibodies for pharma partners. Most directly comparable peer — both monetize via licensing to large pharma and operate technology platforms producing antibody candidates across multiple indications.
  • Xaira Therapeutics: AI-first drug discovery company launched in 2024 with $1B Series A, applying generative AI to protein design and small-molecule discovery. Comparable as a recently-funded generative-AI-biologics peer with similar platform ambitions and pharma partnership strategy, though earlier in commercial validation.
  • Recursion Pharmaceuticals: AI-enabled drug discovery company combining high-dimensional biology, chemistry, and ML to discover therapeutics across multiple modalities. Comparable as a publicly-traded AI-drug-discovery peer with a similar platform-licensing and pipeline-development business model, though Recursion's pipeline is more small-molecule weighted.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Earendil Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Earendil Labs leadership team

Management profile

Number of profiles

Profiles2 records

Earendil Labs funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Earendil Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Earendil Labs

What does Earendil Labs do?

Earendil Labs develops an AI-driven biologics discovery platform that combines deep learning, generative protein engineering, structural biology, and high-throughput experimental validation to discover and optimize novel antibody therapeutics. The company applies this platform to build a pipeline of more than 40 biologics programs across autoimmune, inflammatory, and oncology indications, which it out-licenses to large pharmaceutical partners for development and commercialization.

Is Earendil Labs a public or private company?

Earendil Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Earendil Labs founded?

Earendil Labs was founded in 2021. It employs 11 to 50 people.

Where is Earendil Labs based?

Earendil Labs is headquartered in Middletown, United States, in the North America region.

How does Earendil Labs make money?

Two revenue lines are on record. Strategic Partnerships and Licensing is the primary driver. The others are technology Licensing.

Who are Earendil Labs's main competitors?

Emerging players on record are BigHat Biosciences, Antiverse and EvolutionaryScale (ESM). Direct peers are Insitro, Isomorphic Labs, Generate Biomedicines, Adimab, AbCellera Biologics, Xaira Therapeutics and Recursion Pharmaceuticals.

Does Earendil Labs have an API?

No public API is recorded for Earendil Labs.

What industry is Earendil Labs in?

Earendil Labs's product category is Biologics Drug Discovery. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmaceutical TechnologyRoche and Earendil forge $1.5bn bispecific discovery deal - Pharmaceutical TechnologyGenentech agreed with Earendil Labs to develop bispecific antibodies for oncology, paying $55m upfront and up to $1.445bn in milestones. Earendil will handle early development, with Genentech taking over later, and Earendil may earn tiered royalties. The deal follows Sanofi's $2.56bn agreement with Earendil.European BiotechnologyRoche signs two deals worth about $3.5B in one dayRoche signed two research partnerships on Sept. 24 with Atavistik Bio and Earendil Labs, totaling over $3.47 billion in potential value. Roche paid $125 million upfront, with Atavistik receiving $70 million and Earendil $55 million. The deals are Roche's fourth and fifth biotech agreements in less than a month.Unite.AIEarendil Labs Partners With Genentech on Bispecific Cancer AntibodiesEarendil Labs announced a collaboration with Genentech to develop bispecific cancer antibodies, with a $55 million upfront payment and potential value exceeding $1.5 billion. Earendil will lead discovery through early clinical development, while Genentech takes over global clinical development and commercialization. The deal follows similar agreements with Sanofi and WuXi Biologics.PR NewswireEarendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies in OncologyEarendil Labs announced a research collaboration with Genentech to discover and develop bispecific antibody programs in oncology. Earendil will lead discovery through early clinical development, while Genentech handles later development and commercialization. The deal includes a $55 million upfront payment and potential total value exceeding $1.5 billion.ChinaventureByte's 'favorite son' unveils the capital landscape of AI pharmaceuticals.Anew Labs, an AI pharmaceutical company spun off from ByteDance, completed a $290 million Series A financing round led by Sequoia China, IDG Capital, and Hillhouse Capital. The post-investment valuation reached $1.5 billion, with China Biopharmaceutical as a strategic investor.ThewirechinaThe Daily RoundupEarendil, a Chinese AI biotechnology company, faces regulatory hurdles as it seeks an IPO in Hong Kong due to concerns over its "red-chip" holding structure. Meanwhile, GM and China’s SAIC have extended their joint venture partnership for another 20 years, planning to launch at least 30 new-energy vehicles by 2030. The developments highlight the complex landscape for foreign finance in China and the ongoing evolution of joint ventures in the new-energy sector.WsjEarendil Hits Regulatory Hurdle as It Seeks Hong Kong IPOEarendil Labs, a Chinese AI biotech, is seeking a $5 billion valuation in a Hong Kong IPO, planning to raise nearly $400 million. The company submitted its IPO application to Chinese regulators, who have raised concerns over its "red-chip" holding structure.WewillcureCure’s AI Drug Discovery Funding Tracker 2026Cure's funding tracker documents major AI drug discovery venture rounds of $10M or more across January through May 2026, with no new $10M+ rounds confirmed for June 2026. Isomorphic Labs raised the largest round at $2.1B Series B (bringing total funding to roughly $2.7B), making it the second-largest biotech fundraising in history after Altos Labs' $5.5B combined investment; the company is headquartered in London with a second location in Lausanne, Switzerland, and was founded by Demis Hassabis as an Alphabet-founded firm. The sector saw diverse funding activity spanning seed through Series B rounds for companies developing AI platforms spanning end-to-end drug discovery, protein design, biologics development, and molecular generation, with notable raises including Earendil Labs ($787M), Fathom Therapeutics ($47M Series A), Alloy Therapeutics ($40M Series E at $1B valuation), Galux ($29M Series B), VantAI/Proxima ($80M seed), and Generate (€20M/$23M Series A).The Medicine MakerEarendil: A Blueprint for a Multipolar Life Sciences EraOn March 20, 2026, Earendil Labs announced $787 million in financing—one of the largest private rounds in AI-enabled drug discovery—featuring an investor syndicate including Dimension Capital, DST Global Partners, Sanofi, and the Hillhouse-Pfizer Biotech Development Fund. The company, incorporated in Delaware with Beijing headquarters and reportedly considering a Hong Kong IPO, exemplifies a multipolar business model combining European research partnerships (Sanofi's $2.56 billion strategic collaboration), American AI infrastructure, and Chinese operational execution. The article positions this financing as a case study in how next-generation life sciences companies are deliberately integrating geography, capital origin, and operational location as complementary assets, amid ongoing BIOSECURE Act tensions and US-China trade dynamics.PR NewswireEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)Earendil Labs announced the successful completion of cohort 1 dosing in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). Preclinical studies demonstrated that HXN-1011 exhibits more potent activity and longer-lasting pharmacodynamic effects compared to several benchmark products currently under clinical development. The company is developing HXN-1011 for treatment of immunological disorders including asthma, atopic dermatitis, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.